In addition, Metsera has granted the underwriters a 30-day option to purchase up to an additional 2,291,666 shares of common stock at the initial public offering price less underwriting discounts ...

In addition, Metsera today announced the exercise in full by the underwriters of their option to purchase 2,291,666 additional shares, at the initial public offering price of $18.00 per share ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...

Metsera’s (NASDAQ:MTSR – Get Free Report) quiet period is set to expire on Wednesday, March 12th. Metsera had issued 15,277,778 shares in its initial public offering on January 31st. The total size of ...

Metsera Inc. MTSR, a New York-based biotech that went public on Jan. 31 with some fanfare, has a full portfolio of weight-loss drugs in development, using both the hormones already used in ...

On February 3, three insiders purchased a total of around $94.22 million worth of Metsera shares during the company’s initial public offering. Insiders acquired shares at a price of $18 per share.

In addition, Metsera today announced the exercise in full by the underwriters of their option to purchase 2,291,666 additional shares, at the initial public offering price of $18.00 per share, and the ...